Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio
This version of our ongoing better buy series pits two development-stage biotechs, Bellicum Pharmaceuticals (NASDAQ: BLCM) and bluebird bio (NASDAQ: BLUE), against each other. The companies have something in common -- they're both developing chimeric antigen receptor T-cell (CAR-T) therapies to treat cancer -- but they've both got something else up their sleeves.
CAR-T technology and the related T cell receptor (TCR) technology both involve taking immune cells out of patients, inserting DNA that trains the immune cells to attack cancer cells expressing a certain protein, and then putting the cells back into the patient to do their work.
While both Bellicum Pharmaceuticals and Bluebird have therapies using CAR-T/TCR, they're not currently competing with each other directly because their respective CAR-T therapies train the immune cells against different targets expressed on different types of tumors.
Source: Fool.com
Bluebird Bio Inc. Aktie
Bluebird Bio Inc. ist kein großer Community-Favorit mit mehr Sell- als Buy-Einschätzungen.
Obwohl das Kursziel für Bluebird Bio Inc. bei 6 € liegt, was über dem aktuellen Kurs von 1.03 € ist, zeigt sich ein Potenzial von 481.68%.
